Skip to main content

Table 1 Subgroup analysis of the any grade adverse events

From: The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis

Experimental vs. control

No. of studies

RR

95% CI

p

Heterogeneity

(I2) (%)

Any grade adverse events

8

1.04

0.99–1.10

0.16

97

Any grade abdominal pain

9

0.97

0.84–1.12

0.68

36

Any grade anemia

9

3.40

1.86–6.19

< 0.001

95

Any grade arthralgia

7

0.94

0.82–1.07

0.32

0

Any grade constipation

9

1.16

0.91–1.49

0.22

75

Any grade decreased appetite

6

1.45

1.21–1.74

< 0.001

7

Any grade diarrhea

8

1.23

1.07–1.40

0.003

20

Any grade dizziness

6

1.46

1.11–1.94

0.008

36

Any grade fatigue

9

1.36

1.20–1.53

< 0.001

65

Any grade headache

8

1.35

1.04–1.74

0.02

68

Any grade nausea

9

1.71

1.35–2.17

< 0.001

92

Any grade neutropenia

8

1.88

1.23–2.87

0.003

89

Any grade thrombocytopenia

7

3.59

1.65–7.78

0.001

91

Any grade vomiting

9

1.82

1.48–2.23

< 0.001

60